Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 4, 2017
Event: Entry into a Material Definitive Agreement (Commercialization Agreement) with Depomed, Inc. for the U.S. commercialization of Nucynta ER and IR products.
Key Financial Metrics and Obligations
This filing details contractual financial obligations rather than historical performance metrics. Key financial terms include:
- Upfront License Fee: $10.0 million non-refundable payment due at closing (expected January 1, 2018).
- Minimum Royalties (2018–2021): $135.0 million per year, payable quarterly ($33.75 million per quarter).
- Additional Royalties (2018–2021): 25% of net sales between $233M and $258M; 17.5% of net sales above $258M.
- Post-2021 Royalties: No guaranteed minimum. Tiered royalties apply: 58% on sales up to $233M, 25% on sales between $233M and $258M, and 17.5% on sales above $258M.
- Security: Obligations secured by a first-priority security interest in Collegium NF's property and equity, plus a standby letter of credit.
Material Changes and Contractual Terms
The agreement represents a significant shift in the Company's business model, transitioning to a commercialization role for Depomed's products. Key structural terms include:
- Exclusivity: Collegium is prohibited from developing or selling competing centrally acting opioid analgesics of the benzenoid class in the Territory.
- Supply Guarantees: If Depomed fails to deliver ordered quantities for two months or longer in 2018, Depomed may be required to offset minimum royalties to ensure Collegium receives a minimum gross profit level.
- Termination Rights:
- Depomed: May terminate without penalty if annual net sales fall below $180M through Jan 1, 2022, or below $140M in any 12-month period thereafter. May terminate for convenience prior to Dec 31, 2018, subject to a fee.
- Collegium: May terminate after the first anniversary with one year's notice. Termination prior to the fourth anniversary requires a $25.0 million fee.
Outlook, Risks, and Contingencies
Closing Conditions: The transaction is subject to customary conditions, including the expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act). If the HSR waiting period is not resolved within 70 days, either party may terminate.
Financial Risks: The Company faces significant fixed cash outflows ($135M annually) regardless of sales performance through 2021. Failure to meet sales thresholds could result in termination by Depomed.
Management Commentary: The filing references a press release and investor presentation (Exhibits 99.1 and 99.2) for further details, though the text of those exhibits is not included in this summary.
Investor Verification Checklist
- Verify the Company's current cash position and liquidity to fund the $10M upfront fee and the $135M annual minimum royalty obligations.
- Confirm the status of the HSR Act waiting period and the expected closing date (targeted for Jan 1, 2018).
- Review the supply chain reliability of Depomed to assess the risk of triggering the gross profit offset provision.
- Assess the impact of the non-compete clause on Collegium's ability to develop its own pipeline in the opioid analgesic space.
- Examine the standby letter of credit requirements and the impact on the Company's credit facilities.